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Objectives: This proof-of-concept study aimed to identify whether mutations considered not yet relevant for
drug resistance (but located at key drug-resistance positions) can act as ‘sentinels’ of minority resistant variants
in HIV-1 drug-naive patients.
Methods: We focused our attention on three reverse transcriptase (RT) mutations (T69S, L210M and K103R)
easily detected by standard population sequencing [i.e. the genotypic resistance test (GRT)]. Ultra-deep pyro-
sequencing (UDPS) of HIV-1 RT was performed using GS-FLX Roche, on plasma RNA from 40 drug-naive patients
infected with HIV-1 subtype B without primary resistance detected by GRT. Only RT drug resistance mutations
detected at .0.1% in both forward and reverse directions were considered. Associations between GRT sentinel
mutations and UDPS drug resistance were assessed using Fisher’s exact test.
Results: UDPS detected drug resistance mutations in 18/40 drug-naive patients. Patients carrying HIV-1 strains with
T69S and L210M by GRT showed a trend to greater infection by minority drug-resistant variants than control patients
infected by HIV-1 without these mutations (5/10 and 7/10 versus 3/10; P¼not significant). No association was found
for K103Rby GRT. Notably, T69S andL210M (but not K103Rorcontrol viruses) were associated withGRTminority drug-
resistant variants with a prevalence.1% (3/10 and 4/10 versus 0/20 in K103R and controls; P¼0.03 and P¼0.008,
respectively). Moreover, the presence of L210M or T69S viruses by GRT significantly correlated with that of minority
thymidine analogue mutations by UDPS (6/20 patients carrying HIV-1 strains with T69S/L210M versus 0/20 patients
carrying HIV-1 having K103R or none of these mutations; P¼0.03).
Conclusions: This proof-of-concept study suggests the existence of genetic markers, detectable by routine testing,
potentially acting as sentinel mutations of minority drug resistance. Their identification may help in the selection
of patients at high risk of resistance in reservoirs without the necessity of using UDPS.
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Introduction
At present, 25 antiretroviral drugs are available for the treatment
of HIV-1. The combined use of several (3 or 4) of these drugs,
known as highly active antiretroviral therapy (HAART), has suc-
cessfully suppressed HIV-1 replication and has dramatically
improved the prognosis of HIV-1-infected patients. However,
when viral load rebound occurs during failing therapy against
HIV-1 infection, viruses with mutations conferring drug resist-
ance can be selected and become dominant in the viral popu-
lation.1 In HAART-treated patients with detectable plasma
HIV-1 RNA, the prevalence of resistance to at least one drug
can reach 80%.2,3
The frequent selection of drug-resistant strains during treat-
ment failure can in turn increase the risk of their transmission
(both predominant and minority species) to new individuals
who are naive to the antiretroviral drugs (drug-naive individuals).
The transmission of drug-resistant HIV-1 strains is well docu-
mented and frequently associated with suboptimal virological
response to initial antiretroviral therapy.4 – 8
Based on the above considerations, the identification of
resistance in drug-naive individuals (also including the minority
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species) is important if a suboptimal response or, worse,
virological failure to first-line antiretroviral therapy, is to be
avoided.9 – 12
The genotypic resistance test (GRT) is considered the standard
of care for detecting drug-resistant strains and is therefore rec-
ommended in both drug-naive and HAART-treated patients.5
However, the sequencing procedure currently used is based on
the Sanger method, which cannot detect viral variants below a
detection threshold of about 15%–20% of the viral quasispecies.
Below this level, drug-resistant variants may therefore be missed
by GRT, suggesting that this test might underestimate the pres-
ence of drug-resistant viruses.
Recently, more sensitive assays, such as ultra-deep pyrosequen-
cing (UDPS), have allowed the assessment of antiretroviral drug
resistance mutations even when present as minority species (with
a prevalence ,20% of the entire viral population).13–15 However,
the implementation of these sensitive tests in clinical practice
remains limited due to their current high cost and complexity.
The aim of this paper was to identify new genetic markers
acting as ‘sentinel’ mutations in HIV-1 reverse transcriptase
(RT) that are detected by population sequencing and are able
to predict the presence of drug-resistant minority species in
patients with no evidence of resistance by GRT. The potential
sentinel mutations considered in this study were three RT
mutations at positions already associated with drug resistance:16
T69S, L210M, and K103R. These mutations are thought not to be
involved in phenotypic resistance to RT inhibitors in either clinical
isolates or site-directed mutagenesis experiments.17,18 Analysis
of 3370 individuals infected with HIV-1 subtype B in our data-
base, all naive to antiretroviral therapy, showed that these atypi-
cal mutations were generally present at low frequencies (T69S,
1.9%; L210M, 0.7%; and K103R, 1.4%). Interestingly, their preva-
lence increased from 0.8%, 0.1% and 0.4% in samples collected
before 2004 to 2.2%, 0.9% and 1.7% in samples collected after
2004, respectively.
Patients and methods
Study population
Among 3370 patients infected with HIV-1 subtype B who were naive to
antiretroviral therapy and under care at ‘L. Spallanzani’ Hospital in
Rome, Italy, between January 2004 and December 2009, 40 patients
were selected: 30 infected by HIV-1 virus with T69S (n¼10), L210M
(n¼10) or K103R (n¼10) by standard GRT; and 10 infected by HIV-1
virus having none of these mutations, used as controls.
All 40 patients matched the following criteria: no previous exposure to
antiretroviral drugs; a viral load .10000 copies/mL at the time of testing;
and complete absence of primary transmitted resistance by standard GRT.19
All patients were coded for anonymity; demographic characteristics,
self-reported route of transmission and date of sampling were analysed,
together with virological, clinical and immunological parameters.
HIV-1 sequencing
Standard population sequencing
HIV genotype analysis was performed on all 40 plasma samples using a
commercial sequencing kit (ViroSeq HIV-1 genotyping system; Abbott
Laboratories).20 Briefly, after 2 h of ultracentrifugation, HIV-1 RNA was
extracted, retrotranscribed with murine leukaemia virus RT and amplified
with Amplitaq-Gold polymerase by using two different sequence-specific
primers for 40 cycles. The amplified products (containing the entire pro-
tease and the first 335 amino acids of the RT open reading frame; 1302
nucleotides) were full-length-sequenced in sense and antisense orien-
tations using an automated sequencer (ABI 3100) with seven different
overlapping sequence-specific primers.20 Sequences having a mixture of
wild-type and mutant residues at single positions were considered to
have the mutant(s) at that position.
UDPS
After RNA extraction (performed as for standard sequencing), UDPS of RT
was performed on all 40 of the samples.
UDPS was carried out using the 454 Life Sciences platform (GS-FLX;
Roche Applied Science), using the HIV prototype primer set and sequen-
cing protocol of the 2009 HIV Alphasite Study, supported by Roche.21
Briefly, three overlapping cDNA sequences provided the source material
for eight partially overlapping amplicons spanning the entire protease
and RT codons, which were generated using barcoded primers. PCR
products were then clonally amplified on capture beads in water-in-oil
emulsion micro-reactors, and pyrosequencing was performed, following
the standard approach for PCR amplicon sequencing. For each sample
a Standard Flowgram Format (SFF) file was obtained, from which
nucleotide sequence data were extracted.
GS Amplicon Variant Analyzer (AVA) software was used to analyse the
UDPS results, as described by Simen et al.14 Sequences from both
orientations and from overlapping amplicons were combined into a
single alignment, and primer regions were automatically trimmed to
avoid artefacts from the nucleotide content of the synthesized primers.
UDPS generated a median of 7404 sequences per sample with a
median sequence length of 245 bases. At least 300 sequences per
base was considered the minimum accepted sequence coverage for
each position of interest. Median coverage was 1200 sequences per
base (range 300–6145).
Determination of drug-resistant minority variants
To estimate the prevalence of RT drug-resistant minority variants in the
selected group of drug-naive patients, we used the list of drug resistance
mutations reported in bold by Johnson et al.16 and by the Stanford HIV
Drug Resistance Database (http://hivdb.stanford.edu/, last update June
2008). For each patient and for each drug resistance mutation, we deter-
mined the percentage of RT mutated sequences as well as their viral
concentration (mutational load), calculated using the formula: percentage
(%) of sequences containing each mutation×contextual viral load.22
Drug resistance mutations detected at a level of .2.0% of viral
species in both forward and reverse directions were considered authentic
minor variants. Drug resistance mutations detected at a level of .0.1%
and ,2.0% of viral species in both forward and reverse directions were
considered authentic minority variants only if the relationship presented
by Wang et al.23 between the number of required sequences per position
(required coverage) and the frequency of a given minority sequence
variant (detection threshold) was guaranteed.
We also analysed all mutations found in the same amplicon to
investigate any drug resistance pattern. Further analysis (i.e. haplotype
reconstruction) was not attempted, due to the RT length and the high
number of overlapping amplicons used to cover it.
Statistical analysis
Potential differences among the four groups of patients were assessed
with the x2 test for trend for categorical variables and the Kruskal–
Wallis test for continuous variables.
Alteri et al.
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The association between sentinel mutations revealed by standard GRT
and drug-resistant minor variants revealed by UPDS was assessed using
Fisher’s exact test.
The role of minority drug-resistant variants found in drug-naive
patients in the virological outcome was also evaluated in patients
starting their first-line treatment (n¼32). The time needed to reach
a plasma HIV-1 RNA level of ,50 copies/mL after the start of
treatment was determined, and compared between patients with and
without drug-resistant minority variants using the Wilcoxon rank-sum
test.
Results
Study population
Table 1 shows the epidemiological and viro-immunological
characteristics of the 40 patients analysed.
At the time of the GRT, performed after a median time
of 0.8 years [interquartile range (IQR) 0.1–3.7] since HIV diag-
nosis, patients had a median CD4 cell count of 239 cells/mm3
(IQR 66–345) and a median viral load of 5.0 log copies/mL
(IQR 4.5–5.5). No differences were reported among the four
groups of patients, with the exceptions of HIV exposure and
CD4 cell count at baseline (Table 1).
After GRT, 32 patients started an antiretroviral treatment.
Among patients for whom the therapeutic regimen was
known, 14 started a regimen containing two nucleoside
RT inhibitors (NRTIs) plus one protease inhibitor (PI), 10 started
with two NRTIs plus one non-NRTI (NNRTI), 2 started
with three NRTIs plus one PI and 1 started with two NRTIs.
Two other patients started a regimen containing raltegravir in
combination with two NRTIs and two NRTIs plus one PI,
respectively.
UDPS results for each patient analysed are reported in Table 2.
Coverage profile and UDPS results
The mean number of sequences obtained for each RT position is
shown in Figure 1.
Focusing our analysis on the RT positions known to be associ-
ated with RT inhibitor (RTI) resistance, we found that UDPS
detected minority variants with at least one RT resistance
mutation in 18/40 patients (45.0%); of these, 7 patients carried
drug resistance minority variants with prevalence .1%. Ten indi-
viduals carried only NRTI minority variants, three individuals
carried only NNRTI minority variants and five individuals carried
both NRTI and NNRTI minority variants.
The thymidine analogue mutations (TAMs) were the most fre-
quently observed mutations (6/40 patients), with a prevalence in
the viral quasispecies ranging from 0.40% for T215Y and K70R to
1.81% for D67N in the viral population. Other mutations found
as minor species were the NRTI mutation F77L, involved in the
Q151M complex, and the NNRTI mutations G190A/E, each
observed in 4/40 patients. K103N and M184V mutations were
also found by UDPS in two patients with a prevalence of 2.6%
and 4.2%, respectively, and in four patients with a prevalence
,2% (ranging from 0.49% to 1.14%).
Additional mutations, including the T215 revertants A/N/I/D
and the NNRTI V106I and V179D mutations, were found in 4, 3
and 2 patients, respectively, with a prevalence ranging from
0.32% to 1.35% for the T215 revertants and from 0.85% to
4.6% for the NNRTI mutations.
Role of sentinel RT mutations in predicting minority
resistant variants
Prevalence of drug-resistant minority variants
By UDPS, patients infected with HIV-1 virus who had T69S or
L210M by standard GRT showed a trend to greater infection by
Table 1. Demographic, clinical and virological characteristics of the 40 patients
Overall
Samples with mutations detected by GRT
P valueacontrol virus K103R T69S L210M
Number of patients 40 10 10 10 10
Year of HIV-1 diagnosis, median (IQR) 2005 (2003–06) 2002 (2000–06) 2005 (2003–05) 2005 (2002–06) 2006 (2005–08) NS
Time since HIV-1 diagnosis (years), median (IQR) 0.8 (0.1–3.7) 2.9 (0.1–6.5) 0.3 (0.2–4.1) 0.9 (0.2–3.2) 0.4 (0.1–2.0) NS
Male, n (%) 34 (85.0) 9 (90.0) 10 (100.0) 6 (60.0) 9 (90.0) NS
HIV exposure, n (%)
MSM 9 (22.5) 3 (30.0) 0 (0.0) 1 (10.0) 5 (50.0) 0.03
heterosexual 8 (19.5) 1 (10.0) 2 (20.0) 5 (50.0) 0 (0.0) 0.03
injection drug users 7 (17.1) 3 (30.0) 3 (30.0) 1 (10.0) 0 (0.0) NS
other or unknown 16 (39.0) 3 (30.0) 5 (50.0) 3 (30.0) 5 (50.0) NS
Age (years), median (IQR) 39 (33–44) 42 (40–44) 44 (41–49) 38 (36–39) 33 (27–41) NS
Patients starting a first-line regimen, n (%) 32 (80.0) 9 (90.0) 7 (70.0) 10 (100.0) 6 (60.0)
Viraemia (log copies/mL), median (IQR) 5.0 (4.5–5.5) 5.0 (4.8–5.6) 5.0 (4.6–5.3) 5.3 (4.5–5.7) 4.8 (4.3–5.2) NS
CD4 cell count (cells/mm3), median (IQR) 239 (66–345) 142 (46–272) 70 (25–189) 170 (64–327) 559 (270–897) 0.02
No. of DNA samples available 9 2 4 1 2
MSM, men who have sex with men; NS, not significant.
aStatistically significant differences among the four groups of patients were assessed by the x2 test for trend for categorical data and the Kruskal–
Wallis test for continuous variables.
HIV-1 reverse transcriptase sentinel mutations and minority drug resistance
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minority RT drug-resistant variants than control patients (5/10
and 7/10 versus 3/10; not significant, P¼0.20) (Figure 2). Conver-
sely, for patients carrying HIV-1 virus with K103R by standard
GRT, UDPS revealed the same level of minority resistance
(3/10) as control viruses.
Of note, minority drug-resistant species with a prevalence
of .1% (predictors of poor treatment outcomes24 – 26) were
observed only in patients infected with T69S or L210M viruses.
In particular, three patients with T69S and four patients with
L210M carried minority RT resistance variants with a mutation
Table 2. Clinical characteristics, UDPS results, HAART therapy and virological response for 40 antiretroviral-naive persons analysed by standard direct
PCR Sanger sequencing
Patient
number
Transmission
route
Date of
diagnosis
CD4 count
(cells/mm3)a
HIV-1 RNA
(log copies/mL)b
Atypical
mutationc Minority drug resistance (% of reads with mutation)d
2580 unknown 15/08/2003 235 4.03 L210M M184V (1.14); K219Q (0.8); V179D (1.06)
4027 homosexual 01/10/2005 1134 5.70 L210M M41L (0.76); L74V(2.38); V108I (1.51)
5581 homosexual 15/12/2004 1128 4.36 L210M F77L (0.27)
7755 homosexual 27/06/2008 270 5.24 L210M M41L (1.75); M184V(0.49); T215FY (0.40); K103N (2.6);
G190A (0.35)
8889 homosexual 27/07/2009 820 4.08 L210M F77L (0.55); G190E (0.95)
8893 homosexual NA NA 4.21 L210M A62V (0.82); F77L (0.57) G190E (1.1)
7567 unknown 09/01/2006 271 4.55 L210M none
8932 homosexual 01/01/2009 NA 5.47 L210M V75I (0.89); G190E (0.47)
4780 homosexual 01/07/2004 783 5.23 L210M none
4095 homosexual 23/12/2005 336 4.79 L210M none
1749 heterosexual 01/03/1999 727 4.30 T69S none
3268 heterosexual 01/11/2003 63 4.63 T69S D67N (1.81)
3742 unknown 01/01/2006 65 5.70 T69S V75I (0.70); V106I (0.85)
4004 unknown 01/01/2002 264 5.34 T69S L210W (0.53); V106I (4.6)
5603 heterosexual 01/05/2006 457 4.48 T69S K103N (4.2)
6534 drug user 01/05/2007 30 5.70 T69S T215N (0.38)
6565 homosexual 12/06/2006 345 4.28 T69S A62V (1.70); K70R (0.40)
7587 unknown 01/01/2002 271 5.23 T69S none
2667 heterosexual 15/10/2004 20 5.70 T69S none
8502 heterosexual 01/03/2009 76 5.93 T69S none
3012 drug user 16/02/2005 90 5.70 none none
4845 homosexual 17/02/2006 281 5.62 none V106A (0.97)
7070 heterosexual 01/09/2007 19 4.95 none F77L (0.92); T215I (1.1)
2773 drug user NA 174 4.80 none none
7253 homosexual 20/11/2006 487 5.02 none none
7644 drug user NA 1269 4.06 none none
5171 unknown 01/01/2000 21 4.47 none M184V (0.54)
5202 homosexual 01/08/2000 31 5.70 none none
5732 unknown NA 243 5.06 none none
7169 unknown NA 111 5.44 none none
2990 homosexual 01/01/2005 25 5.47 K103R none
3726 drug user 01/01/2000 337 4.87 K103R F77L (0.76)
202 unknown 01/07/2005 69 5.70 K103R T215D (1.35)
4402 unknown NA 8 4.48 K103R T215A (0.32); M184V (0.67)
6335 drug user NA 189 5.20 K103R none
2729 unknown 01/09/2004 25 4.12 K103R none
2799 heterosexual 01/01/2003 147 5.32 K103R none
3267 unknown 15/04/2005 70 4.91 K103R none
7817 drug user 01/07/2008 NA 5.09 K103R V108I (0.56)
8648 heterosexual 17/04/2005 344 4.15 K103R none
aCD4 cell count at GRT.
bPlasma HIV-1 RNA level at GRT.
cAtypical mutation at drug resistance position detected by bulk sequencing.
dPercentages for minority variants are shown in parentheses. Drug resistance mutations are shown in bold, while revertants and minor resistance
mutations are shown in non-bold font.
Alteri et al.
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prevalence .1%, versus none in controls and in K103R samples
(3/10 and 4/10 versus 0/20; P¼0.03 and P¼0.008, respectively)
(Figure 3a).
The higher level of minority drug resistance in patients with
L210M viruses was also confirmed by analysing the mutational
load. As shown in Figure 3(b), six drug resistance mutations in
L210M viruses reached a load of 2650–11900 copies/mL.
These mutations were the TAM M41L, the abacavir/didanosine
resistance mutation L74V, V75I, involved in the 151 complex,
and the NNRTI resistance mutations V108I and K103N. This
suggests a greater chance of these mutations being selected if
there is incomplete control of virus replication.
Association of L210M and T69S with specific drug
resistance mutations
When specific drug resistance mutations were analysed, TAMs
were detected as minority species exclusively in patients with
L210M and T69S sentinel mutations. In particular, six patients,
3/10 with T69S and 3/10 with L210M, carried TAMs versus 0/10
control and 0/10 K103R viruses (P¼0.03). TAM1 and TAM2 path-
ways were also equally distributed in these patients; the mutations
M41L (0.76% and 1.14%), T215FY (0.40%) and K219Q (0.80%)
were found in sequences from patients with L210M by GRT, while
D67N (2.82%), K70R (0.40%) and L210W (0.53%) were found in
sequences from patients with T69S by GRT.
Combination of drug resistance mutations
Sequences obtained by UDPS were also analysed in order to
determine patterns of drug resistance mutations in our samples.
Among the 40 drug-naive patients analysed, only patients
with L210M or T69S viruses by GRT showed more than one
major RT resistance mutation by UDPS (6/10 patients with
L210M and 1/10 with T69S, versus 0/20 in controls and patients
with K103R viruses; P¼0.01) (Figure 2). In three patients, all car-
rying L210M by GRT, drug resistance mutations were localized in
the same viral strain. In particular, in sample no. 7755, 0.33% of
viral strains expressing NRTI T215F also carried NRTI M184V and
NNRTI G190A. In sample 4027 all minority variants expressing
the TAM M41L (0.76% of the viral population) also carried the
mutation L74V, while in sample 2580 all the minority species
with K219Q (0.8%) also carried the NRTI resistance mutation
M184V.
These data suggest that the mutation L210M detected by
standard GRT could be a sentinel of drug resistance minority
species, including multidrug-resistant minority variants.
Response to HAART
Thirty-two out of 40 patients (17 infected with no drug-resistant
minority variants and 15 infected with drug-resistant minority
variants) started an antiretroviral regimen after genotypic
testing (all after 2009). Thirty (93.7%) out of 32 patients
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reached virological success in a median time of 15.8 weeks (IQR
12.0–19.6) after HAART initiation. Interestingly, patients with
minority drug-resistant variants with a prevalence of .1%
reached virological success in a median time of 19.9 weeks
(IQR 14.8–21.0), later than patients with either no or low-
prevalence minority variants (14.1 weeks; IQR 10.7–16.0)
(P¼0.08).
Analysing the plasma HIV-RNA levels from baseline to week
24, we also found that, whereas at weeks 4 and 8 the proportion
of patients who reached virological success (HIV-RNA level
,50 copies/mL) was not different between patients who
carried minor resistance mutations with a prevalence .1% and
those who did not (0/7 versus 0/18 and 0/7 versus 2/18), at
weeks 12 and 24 the proportion of patients who reached virolo-
gical success was slightly lower in patients who carried minor
resistance mutations with a prevalence .1% compared with
those who did not [2/7 versus 13/21 (P¼0.12) and 3/6 versus
18/21 (P¼0.06)].
Discussion
In our group of 40 HIV-1-infected individuals naive to antiretro-
viral drugs and with no evidence of resistance by bulk sequen-
cing, minority drug-resistant variants were detected by UDPS in
18/40 patients with a prevalence ranging from 0.40% to 4.2%
of the entire viral population. The prevalence of drug-naive
patients with minority drug resistance was relatively higher
than previously reported.26 – 28 However, it is important to note
that, so far, most of the results on minority variants have been
obtained by investigating only a few mutations using allele-
specific PCR technology (such as searching for K103N, M184V
and Y181C); thus, the frequency of minority resistant variants
in these studies would certainly be higher if more mutations
had been searched for.
Another reason that could explain the high prevalence of
minority drug resistance mutations in our study may arise from
the selection criterion used; in fact, the presence of specific sen-
tinel mutations in HIV-1 RT, studied for their ability to predict
minority drug resistance, may be responsible for the increased
drug resistance prevalence in the study population.
Indeed, in our study we showed that the prevalence and
patterns of minority drug-resistant strains in drug-naive patients
appear to be dependent on specific mutations that are detect-
able by standard GRT and located at known RT drug resistance
positions, potentially acting as sentinel markers for minority
drug resistance mutations. In particular, patients infected with
HIV-1 viruses carrying L210M and T69S mutations harbour
minority NRTI- and NNRTI-resistant variants more frequently
than those infected by control and/or K103R viruses. Even if
these sentinel markers have low prevalence in the drug-naive
population, their prevalence is similar to that observed for the
classical transmitted drug resistance mutations,29,30 confirming
their potential role as sentinel markers of transmitted drug
resistance.
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The drug resistance mutations more often detected by UDPS
in this study were the NRTI mutations, TAMs (together with T215
revertants) and NNRTI mutations G190A/E and K103N. It is inter-
esting to note that the most common drug resistance mutations
observed also by standard GRT in drug-naive individuals were the
NNRTI resistance mutation K103N, the NRTI T215 revertants and
TAMs.29 – 31
The null or modest viral fitness cost conferred by these
mutations on the virus supports the persistence of these
mutants in the untreated population and highlights their
potential for frequent transmission.
Of note, the atypical mutation L210M could be a sentinel
marker not only of undetected drug resistance but especially of
multidrug-resistant minority variants. Indeed, all three patients
harbouring minority HIV-1 strains with more than one major
drug resistance mutation carried L210M by standard GRT.
The sentinel role of L210M may also be relevant from an epi-
demiological point of view; patients with this mutation acquired
HIV predominantly through the homosexual route, which is
known to be more frequently associated with an increased risk
of drug resistance transmission.29,32 The co-presence of this
mutation with the homosexual transmission route could thus
represent an additional marker of acquired drug resistance.
In addition, the L210M mutation is also associated with
a high detection threshold of drug-resistant minority variants,
frequently up to 1% and with a mutational load up to
2000 copies/mL (3/10 patients). In this regard, Goodman et al.9
recently showed that the presence of the NNRTI mutation
K103N at a level .2000 copies/mL strongly correlated with viro-
logical failure to a first-line efavirenz-containing regimen. In our
cohort of patients, the NNRTI mutation K103N was found in two
patients at .2000 copies/mL: in one L210M-expressing patient
its frequency was 2.6%, corresponding to 4564 copies/mL, and
in one T69S-expressing patient its frequency was 4.2%, corre-
sponding to 3383 copies/mL. Both patients responded to their
first-line therapy (not containing NNRTIs).
Indeed, in this study we have also investigated the virological
response to the first-line regimen in a small group of patients
according to the presence of resistant variants as a minority
population. Interestingly, patients with minority drug resistance
variants with a prevalence of .1% reached virological success
later than patients with either no or low-prevalence minority var-
iants. This finding is consistent with previous studies, suggesting
that transmitted resistance, even if in minority species, could
lead to suboptimal response to first-line therapy.10,12,14,26
However, a limitation of this study is the absence of a long-
term follow-up for our patients, all of whom started the HAART
regimen after 2009, and the fully active treatment received.
Moreover, we cannot exclude the possibility that the small
number of patients analysed may have reduced the statistical
power of the study, in particular preventing any other effect of
these minority drug resistance variants on the virological
response from being seen.
In conclusion, this proof-of-concept study suggests that
specific mutations revealed by standard GRT, such as the RT
mutations L210M and T69S, could be markers of the presence
of undetected drug resistance mutations, but could also act as
sentinels of minority viral strains carrying multiple drug resist-
ance mutations. Due to their low replication capacity in the
absence of drug pressure, drug-resistant variants generally
fade away after transmission, and may became present only
as minority variants in the viral population replicating in the
new host. A detailed map of the association between sentinel
mutations, detected by GRT, and minor drug-resistant variants,
detectable only with high-resolution methods, may therefore
help when selecting patients at high risk of resistance in reser-
voirs. These mutations can thus provide a surrogate marker,
easily detectable by routine testing, of minority drug resistance
mutations.
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